Management of advanced prostate cancer: can we improve on androgen deprivation therapy? (Q37108818)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

review article

1 reference

title

Management of advanced prostate cancer: can we improve on androgen deprivation therapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

John Anderson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Per-Anders Abrahamsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

David Crawford

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Kurt Miller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

11 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

101

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

1497-1501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samples

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Gonadotropin-releasing-hormone-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Is the flare phenomenon clinically significant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

3-Month Formulation of Goserelin Acetate (‘Zoladex’ 10.8-mg Depot) in Advanced Prostate Cancer: Results from an Italian, Open, Multicenter Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07590.X

10.1111/J.1464-410X.2008.07590.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18336613%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference